What is the recommended diagnostic test for phaeochromocytoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnostic Test for Pheochromocytoma

The measurement of plasma free metanephrines is the recommended first-line diagnostic test for pheochromocytoma due to its superior sensitivity (96-100%) and specificity (89-98%). 1

Primary Diagnostic Tests

  • Plasma free metanephrines is the most sensitive test (96-100%) for diagnosing pheochromocytoma and should be the first-choice diagnostic test 1, 2
  • Urinary fractionated metanephrines is an acceptable alternative with high sensitivity (86-97%) and specificity (86-95%), particularly useful in pediatric patients who are continent of urine 1, 3
  • Plasma free metanephrines should ideally be collected from an indwelling venous catheter after the patient has been lying supine for 30 minutes to minimize false positive results 1

Interpretation of Results

  • Results >4 times the upper limit of normal are highly consistent with pheochromocytoma and warrant immediate imaging 1
  • For moderately elevated levels (1-4 times upper limit of normal), consider:
    • Repeat testing in 2 months 1
    • Clonidine suppression testing, which has 100% specificity and 96% sensitivity for distinguishing true from false positive results 1, 3
  • False positive elevations are typically <4 times the upper limit of normal and may occur with:
    • Obesity 1
    • Obstructive sleep apnea 1
    • Use of tricyclic antidepressants 1
    • Certain medications (proper patient preparation is essential) 4

Special Considerations

  • For equivocal plasma test results, a 24-hour urine collection for fractionated metanephrines should be performed as a follow-up test 1, 5
  • Plasma methoxytyramine measurement can help assess the likelihood of malignant disease 5
  • LC-MS/MS analysis is preferred for plasma metanephrine measurement as it minimizes medication interference 1, 4
  • Avoid biopsy of suspected pheochromocytoma lesions due to risk of triggering a hypertensive crisis 5

When to Test

Biochemical testing for pheochromocytoma is indicated in patients with:

  • Early-onset hypertension (<30 years) 1
  • Resistant hypertension 1
  • Paroxysmal hypertension with classic symptoms (headache, palpitations, sweating) 1, 5
  • Significant blood pressure variability 1
  • Family history of pheochromocytoma 1
  • Adrenal incidentalomas 6
  • Genetic predispositions (MEN2, von Hippel-Lindau syndrome, neurofibromatosis type 1, SDH mutations) 6

Diagnostic Algorithm

  1. Measure plasma free metanephrines as first-line test 1, 2
  2. If plasma free metanephrines are unavailable, measure urinary fractionated metanephrines 1, 3
  3. Interpret results based on degree of elevation:
    • ≥4x upper limit: Proceed to imaging (CT or MRI) 1, 3
    • 1-4x upper limit: Repeat testing and consider clonidine suppression test 1, 3
    • Normal: Pheochromocytoma effectively ruled out (due to high negative predictive value) 2, 7

Common Pitfalls

  • Failing to properly prepare patients for testing (medications, posture, fasting status) can lead to false positive results 4, 7
  • Using less sensitive tests like plasma/urinary catecholamines or vanillylmandelic acid as initial screening tests may miss cases 2, 8
  • Proceeding directly to imaging without biochemical confirmation wastes resources and may lead to unnecessary procedures 7
  • Plasma normetanephrine levels show a significant association with age, which should be considered when interpreting results 8

References

Guideline

Diagnosis and Management of Pheochromocytoma in Hypertensive Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnóstico de Feocromocitoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Case report of a phantom pheochromocytoma.

Biochemia medica, 2020

Guideline

Diagnóstico y Manejo del Feocromocitoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Phaeochromocytoma.

Lancet (London, England), 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.